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Background and aims: Research shows inconsistent ﬁndings about the link between muscle dysmorphia (MD) and
eating disorder (ED) symptomatology. The aim of this study is to synthesize the scientiﬁc evidence available on this
topic, the researchers conducted a systematic review and meta-analysis.Methods: The literature search enabled us to
identify 39 published articles, which provided 36 independent estimations of the correlation between the two
variables. Results: Our analysis found a positive association between MD and ED symptoms (r+ = .36; 95%
CI= 0.30, 0.41). Moderator analyses showed that the type of sample and the tools for assessing MD and ED were
statistically associated with the MD–ED effect sizes. The methodological quality of the studies exhibited a positive,
statistically signiﬁcant association with the MD–ED effect sizes. Conclusions: Higher levels of MD were related to
greater ED symptomatology, but several study characteristics may moderate the association between the two
variables. In this study, we discuss limitations and implications for clinical practice and future research.
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INTRODUCTION
In a study of the psychiatric effects of steroid consumption,
Pope, Katz, and Hudson (1993) described a new syndrome
called “reverse anorexia,” due to its similarities with
anorexia nervosa (AN) and subsequently renamed “muscle
dysmorphia” (MD; Pope, Gruber, Choi, Olivardia, &
Phillips, 1997). These authors suggested that MD is a form
of body dysmorphic disorder (BDD) characterized by an
obsessive preoccupation with the size and shape of one’s
muscles, causing signiﬁcant distress or impairment in daily
functioning. Individuals with MD have a preoccupation with
not being sufﬁciently lean and muscular. They believe that
their muscles are smaller than they truly are (Grieve, Truba, &
Bowersox, 2009; Olivardia, 2001), and they perceive
themselves as puny and unattractive (Olivardia, Pope, &
Hudson, 2000). Consequently, they seek even greater mus-
culature and greater leanness to enhance the visibility of their
muscularity (Choi, Pope, & Olivardia, 2002).
Additional symptoms associated with MD include the
following: poor quality of life (Pope et al., 2005; Tod &
Edwards, 2015a; Tod, Edwards, & Cranswick, 2016); higher
rates of mood and anxiety disorders (Cafri, Olivardia, &
Thompson, 2008); risk of obsessive–compulsive symptom-
atology and interpersonal sensitivity (Longobardi, Prino,
Fabris, & Settani, 2017); lower self-esteem and self-perception
(Chaney, 2008; Mitchell, Murray, Cobley, et al., 2017);
increased feelings of loneliness (Chaney, 2008); impairments
in social and occupational functioning (Olivardia et al., 2000;
Pope, Khalsa, & Bhasin, 2017; Tod et al., 2016); and
depression, neuroticism, and perfectionism (Mitchell, Murray,
Cobley, et al., 2017).
MD is more prevalent in males, particularly those who
engage in sports that emphasize increased muscle mass or
power gain, such as weightlifting or bodybuilding (American
Psychiatric Association [APA], 2013; Cella, Iannaccone, &
Cotrufo, 2012; Fabris, Longobardi, Prino, & Settani, 2017;
Pope, Phillips, & Olivardia, 2000). However, studies have
also observed MD symptoms in females (Hale, Diehl,
Weaver, & Briggs, 2013; Readdy, Cardinal, & Watkins,
2011; Robert, Monroe-Chandler, & Gammage, 2009; Tod
et al., 2016). Thus, prior research has shown that both female
and male bodybuilders are at extremely high risk of having
MD symptoms (Hale et al., 2013). The average age of onset
of MD is approximately 19–20 years (Cafri et al., 2008;
Olivardia, 2001), and its etiology is not yet well known
(Grieve, 2007).
At present, the American Psychiatric Association (APA,
2013) recognizes MD as a speciﬁer for BDD in the ﬁfth
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edition of Diagnostic and Statistical Manual of Mental
Health Disorders (DSM-5); therefore, it belongs to the
obsessive–compulsive disorder spectrum. According to the
DSM-5, individuals with MD are preoccupied with the idea
that their body build is too small or insufﬁciently lean or
muscular, even though they have a normal-looking body or
are quite muscular. Consequently, they perform repetitive
behaviors (e.g., mirror checking, excessive grooming,
skin picking, and reassurance seeking) or mental acts
(e.g., comparing their appearance with that of others) in
response to their appearance concerns. Therefore, the body,
level of muscularity, and leanness are the obsession, and the
compulsion is the desire or drive to gain more muscularity or
leanness (Pope et al., 2000; Sandgren & Lavalle, 2018).
Other DSM-5 diagnostic criteria specify the following
necessary traits of the disorder: (a) appearance preoccupa-
tion should cause clinically signiﬁcant distress or im-
pairment in social, occupational, or other important areas
of functioning; and (b) it should not be better explained by
concerns with body fat or weight in an individual whose
symptoms meet diagnostic criteria for an eating disorder.
Several studies have found an association between MD
symptoms and higher levels of ED symptomatology
(Giardino & Procidano, 2012; Goodale, Watkins, &
Cardinal, 2001; Hildebrandt, Schlundt, Langenbucher, &
Chung, 2006; Klimek & Hildebrandt, 2018; Lopez, Pollack,
Gonzales, Pona, & Lundgren, 2015; Mitchell, Murray,
Hoon, et al., 2017; Murray et al., 2012; Olivardia et al.,
2000), little or no control over one’s dietary regime,
compulsive exercise (Olivardia et al., 2000), diet pill use
(McFarland & Kaminski, 2009), vomiting (Hildebrandt
et al., 2006; McFarland & Kaminski, 2009), laxative use
(Hildebrandt et al., 2006), and a prior history of EDs
(Olivardia et al., 2000). Nevertheless, other studies have
failed to ﬁnd an association between MD and ED
symptomatology (e.g., Cafri et al., 2008; Maida &
Armstrong, 2005). For instance, Cafri et al. (2008)
examined the link between MD and EDs in a sample of
weightlifting males who met the current criteria for MD,
past MD, or no history of MD. They administered the
Structured Clinical Interview for DSM Disorders (SCID)
to assess MD and EDs. Their ﬁndings revealed that the MD
group did not show higher rates of EDs, any steroid use, or
steroid abuse/dependence than controls. It is possible that
the SCID was less sensitive than other assessment tools in
detecting the association between MD and ED. Along the
same lines, Maida and Armstrong (2005) carried out a study
with a sample of males who lift weights and manifest a
broad range of attitudes about their bodies, from those
falling within the mainstream to those whose worries may
be classiﬁed as pathological. These authors did not ﬁnd a
relationship between MD symptomatology and the bulimia
subscale from the Eating Disorders Inventory (EDI), but
they found that MD was positively related to variables
measuring symptoms of body dissatisfaction, obsessive–
compulsive disorder, depression, and anxiety.
This variability in the ﬁndings might be partly due to the
different sampling and methodological characteristics of the
studies (Nieuwoudt, Zhou, Coutts, & Booker, 2012). Across
studies, differences exist in the deﬁnition of DM and
the measurement tools used to assess MD and ED
symptomatology (Lavender, Brown, & Murray, 2017;
Lopez-Cuautle, Vazquez-Arevalo, & Mancilla-Diaz,
2016; Mitchell, Murray, Cobley, et al., 2017; Sandgreen &
Lavalle, 2018). Thus, to assess MD, studies have used
different self-report questionnaires and interview schedules,
such as the Muscle Dysmorphic Disorder Inventory (MDDI;
Hildebrandt, Langenbucher, & Schlundt, 2004), three dif-
ferent versions of the Muscle Dysmorphia Inventory (MDI;
Lantz, Rhea, & Cornelius, 2002; Rhea, Lantz, & Cornelius,
2004; Short, 2005), the Muscle Appearance Satisfaction
Scale (MASS; Mayville, Williamson, White, Netemeyer, &
Drab, 2002), the Muscle Dysmorphia Symptom Question-
naire (MDSQ; Olivardia et al., 2000), Hale’s Scale (Hale,
2008), and the Muscle Dysmorphia Questionnaire
(Cubberley, 2009). To assess ED symptomatology, studies
have used the Eating Disorder Examination Questionnaire
(EDE-Q; Fairburn & Beglin, 1994), the EDI (Garner,
Olmstead, & Polivy, 1983), or the Eating Attitudes Test-
26 (EAT-26; Garner, Olmstead, Bohr, & Garﬁnkel, 1982).
The studies also differ in the sampling procedure
(e.g., convenience sample vs. probabilistic sample), the
target population investigated [e.g., non-clinical samples:
university students, athletes, and bodybuilders; clinical
samples: MD-diagnosed participants, AN-diagnosed
participants, and people who use anabolic androgenic ste-
roid (AAS)], the gender of the participants (e.g., only males,
only females, or mixed samples), the geographical location
(USA, Australia, Mexico, Italy, Spain, etc.), and the ethnic-
ity of the participants (Sandgren & Lavalle, 2018; Suffolk,
Dovey, Goodwin, & Meyer, 2013).
To the best of our knowledge, no one has yet systemati-
cally studied the association between MD and ED symptom-
atology using a meta-analysis. A prior meta-analysis
synthesized the evidence about the relationship between the
drive for muscularity (DFM) and ED symptomatology,
obtaining an average correlation of r+ = .27 and indicating
that higher levels of DFM were associated with higher levels
of ED psychopathology (Tod & Edwards, 2015b). Based on
Cohen (1988), correlation coefﬁcients of about .1, .3, and .5
can be interpreted as reﬂecting small, moderate, and large
associations, respectively. Therefore, Todd and Edwards’s
(2015b) ﬁndings showed a small to moderate association
between DFM and ED symptomatology. Nevertheless, DFM
and MD are different but related constructs. The former
describes individual motivation to become more muscular,
whereas the latter is a psychological disorder that represents
the pathological pursuit of muscularity and leanness (Cafri
et al., 2005). Hence, the desire to increase muscularity
(i.e., DFM) does not imply distress (i.e., MD; Kimmel &
Mahalik, 2004; Morrison, Morrison, & McCann, 2006).
Therefore, people can present a high DFM without necessar-
ily being distressed by perceived inadequacy or developing
MD. Thus, the research has shown that individuals with MD
are different from normal weightlifters in their symptom
pathology and psychiatric comorbidity (Cafri et al., 2008;
Olivardia et al., 2000). Recent evidence suggests that the
former has a greater presence of eating disordered attitudes
and beliefs than the latter (Mitchell, Murray, Hoon, et al.,
2017; Murray, Nagata, et al., 2017). In addition, research also
suggests that these constructs may have different neuropsy-
chological correlates (Grifﬁths, Murray, & Touyz, 2013).
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Therefore, we primarily aimed to conduct a systematic
review and meta-analysis to synthesize the scientiﬁc
evidence about the relationships between MD and ED
symptomatology, given the inconsistencies in the results
from empirical studies that have previously investigated this
association. A second aim was to identify the study char-
acteristics that might moderate the heterogeneous results
that emerged, such as the geographic location, type of
sample, measurement instruments for MD and ED, age,
gender, and ethnicity, among others.
METHODS
We conducted a systematic review and meta-analysis on the
relationship between MD and ED symptomatology follow-
ing the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (Moher, Liberati,
Tetzlaff, Altman, & The PRISMA Group, 2009). Because
PRISMA guidelines were developed to be applied to meta-
analyses studying intervention efﬁcacy, some of their items
were not applicable to our meta-analysis. Consequently, we
also adhered to the guidelines recently proposed by the
American Psychological Association Publications and
Communications Board Task Force (Appelbaum et al.,
2018, Table 9, p. 2123).
Study selection criteria
The studies had to meet the following inclusion criteria:
(a) the study had to be published in a peer-reviewed journal,
(b) it had to be an original and quantitative investigation,
(c) it had to assess MD using measurement instruments that
speciﬁcally evaluated the symptoms and diagnostic criteria
of MD (e.g., MASS, MDDI, MDI, etc.), (d) it had to assess
ED using measurement instruments that speciﬁcally evalu-
ated the symptoms and/or diagnostic criteria of ED
(e.g., EAT, EDI, and EDE), and (e) it had to empirically
examine the relationship between MD and ED symptoms.
We established no date, language, or participant’s age limits.
We excluded qualitative studies, literature reviews, system-
atic reviews, meta-analyses, commentaries, editorials, and
studies that did not assess MD and its relationship with ED
symptomatology.
Search strategy
The researchers carried out electronic searches in June 2018
in the Medline (via PubMed), PsycInfo, Science Direct, and
Web of Science databases, using the following terms in ALL
FIELDS: muscle dysmorph*, MDI, reverse anorexia,
bigorexia, vigorexia, and Adonis complex. Furthermore,
we conducted manual searches of lists of references from
the retrieved studies to identify additional studies that met
the selection criteria. This search yielded two additional
eligible studies. In addition, the researchers screened lists of
references from previous reviews and meta-analyses
(e.g., Dos Santos, Tirico, Stefano, Touyz, & Claudino,
2015; Mitchell, Murray, Cobley, et al., 2017; Sandegren &
Lavalle, 2018; Suffolk et al., 2013; Tod & Edwards, 2015b)
to ﬁnd studies that met the inclusion criteria for the present
meta-analysis. Finally, in order to locate unpublished
papers, the researchers sent e-mails to 12 of the most proliﬁc
authors in the ﬁeld. Of the six responses we received, none
led to the discovery of an unpublished study.
Two researchers carried out the eligibility process for this
meta-analysis independently, resolving disagreements be-
tween raters by consensus. Figure 1 presents a ﬂowchart of
the study screening and selection process.
Coding of the studies
The researchers produced a protocol for extracting the
characteristics of the studies and applied it to each study.
The following characteristics were coded: year of the study,
geographical location, sampling method, type of sample
(e.g., clinical, community, gymnasiums, university, and
AAS users), sample size, gender, mean age, sexual orienta-
tion, ethnicity, education level, tools used for assessing MD
and ED, and statistics reported to calculate the effect sizes.
In addition, the researchers assessed the methodological
quality of the studies by applying an ad hoc 10-item
checklist, given that in the literature there is no clear
methodological checklist to use in studies with a cross-
sectional design where the purpose is to analyze the relation-
ships between two variables, as in this study. Most quality
checklists are designed for randomized trials and other types
of research, particularly evaluations of interventions
(e.g., Cochrane checklist). Therefore, their criteria focus on
interventions and follow-up assessments. Other checklists
are focused on cohort studies (e.g., Quality Assessment Tool
for Observational Cohort and Cross-Sectional Studies from
National Institutes of Health); however, most of their items
are also related to interventions and follow-up assessments.
Therefore, we developed our own criteria to assess the
methodological quality of primary studies.
Appendix A shows each of the 10 items on the quality
checklist. Each item scored 1 when the study met the criteria
and 0 otherwise. We calculated a total quality score (TQS)
for each study by adding up all the corresponding quality
item scores (range: 0–10), with a higher score indicating
higher overall quality.
The researchers carried out the coding process in a
standardized and systematic manner and two reviewers
independently extracted the data. Interrater reliability was
satisfactory, with a mean intraclass correlation of .98
(SD= 0.036), ranging from 0.90 to 1 for continuous
variables, and with a mean κ coefﬁcient of 0.92 (SD=
0.078), ranging from 0.81 to 1 for qualitative variables.
Inconsistencies between coders were resolved by consensus.
Computing effect sizes
The effect size index was a correlation coefﬁcient (e.g., the
Pearson’s correlation coefﬁcient, its Fisher’s Z transforma-
tion, the ϕ coefﬁcient, the point-biserial correlation
coefﬁcient) calculated between an MD scale and an ED scale
(Borenstein, Hedges, Higgins, & Rothstein, 2009). For each
study, the researchers translated the Pearson’s correlations to
Fisher’s Z in order to normalize their distributions and
stabilize their variances. Then, the researchers back-translated
the Fisher’s Z values for the individual effect sizes, as well as
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those for the mean effect sizes and their conﬁdence limits,
into the Pearson’s correlation metric in order to make their
interpretation easier (Borenstein et al., 2009).
In studies that reported several correlations for the
MD–ED relationship, because researchers used multiple
measures of MD and/or ED, we calculated their average
to avoid statistical dependence.
In studies that did not directly report correlation
coefﬁcients, we applied appropriate translations between
effect sizes. Thus, several studied reported odds ratios (ORs;
Bo et al., 2014; Cafri et al., 2008; Olivardia et al., 2000;
Pope et al., 2005), and we applied a formula to transform
them into correlation coefﬁcients. For each study, the ORs
were translated into d, with d = LogeðORÞ1.65 , Loge being the
natural logarithm. Then, the ds were translated into r, with
r= dﬃﬃﬃﬃﬃﬃﬃﬃ
d2þa
p , where a was estimated with a= ðn1þn2Þ2n1·n2 , and n1,
n2 were the sample sizes in the two conditions
(Sánchez-Meca, Marín-Martínez, & Chaco´n-Moscoso,
2003).
Statistical analyses
The researchers carried out a meta-analysis to assess the
relationship between MD and ED symptomatology. In order
to accommodate the variability shown by the effect sizes, we
assumed a random-effects model (Borenstein et al., 2009;
Sánchez-Meca & Marín-Martínez, 2008). We calculated a
pooled correlation coefﬁcient and its corresponding 95%
conﬁdence interval (CI). In addition, we assessed the statis-
tical signiﬁcance of the pooled correlation using the Z test.
The researchers constructed a forest plot to represent the
individual and pooled effect size estimates, with their 95%
CIs, and to allow visual inspection of effect size heteroge-
neity. We calculated both Cochran’s Q statistic and the
I2 index to assess the consistency of the effect sizes
(Borenstein et al., 2009; Huedo-Medina, Sánchez-Meca,
Marín-Martínez, & Botella, 2006). A Q statistic with
p< .05 was indicative of heterogeneity among the effect
sizes. We estimated the degree of this heterogeneity using
the I2 index. I2 values of around 25%, 50%, and 75% denoted
low, moderate, and large heterogeneity, respectively.
To examine the inﬂuence of moderator variables on
effect size variability, the researchers calculated analyses
of variance (ANOVAs) and meta-regressions for categorical
and continuous variables, respectively, by assuming a
mixed-effects model (Borenstein et al., 2009; Lo´pez-Lo´pez,
Marín-Martínez, Sánchez-Meca, van den Noortgate, &
Viechtbauer, 2014). We assessed the statistical signiﬁcance
of qualitative and continuous moderators with the QB and
QR statistics, respectively. In addition, we calculated an
estimate of the proportion of variance accounted for
by the moderator variable following Raudenbush’s (2009)
proposal (Lo´pez-Lo´pez et al., 2014). We assessed the model
Figure 1. Flowchart of the study selection process in the systematic review and meta-analysis of MD and ED symptomatology
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misspeciﬁcation with the QW and QE statistics for qualita-
tive and continuous moderators, respectively.
Finally, to assess publication bias, the researchers used
both a funnel plot with Duval and Tweedie’s trim-and-ﬁll
method for imputing missing data and the Egger’s test
(Duval & Tweedie, 2000; Sterne & Egger, 2005). A funnel
plot with Duval and Tweedie’s trim-and-ﬁll method uses
available data to impute missing (unreported) studies and
recalculates the overall effect that would be observed with
their inclusion (Duval & Tweedie, 2000). The Egger’s test is
an unweighted simple regression, which takes the precision
of each study as the independent variable (precision being
deﬁned as the inverse of the standard error of each effect
size) and the effect size divided by its standard error as the
dependent variable. A non-statistically signiﬁcant result of
the t-test for the hypothesis of an intercept equal to zero
means that publication bias can be eliminated as a threat to
the validity of the pooled effect (Sterne & Egger, 2005).
The researchers interpreted all statistical tests assuming a
signiﬁcance level of 5% (p< .05). The statistical analyses
were performed with the Comprehensive Meta-analysis
software program, version 3.0 (Biostat, Englewood, NJ,
USA; Borenstein, Hedges, Higgins, & Rothstein, 2014).
RESULTS
Study selection
The search strategy produced a total of 3,575 manuscripts.
After scanning the titles and abstracts of the 3,575 identiﬁed
manuscripts, the researchers preselected 544 relevant stud-
ies based on the inclusion and exclusion criteria. Then,
eliminating duplicates (n= 405) left a total of 139 studies to
review. After a review of the full text of the remaining
articles, 39 fulﬁlled the selection criteria. Nevertheless, nine
articles did not report a correlation between MD and ED or
statistical data to calculate it. In these cases, the researchers
sent e-mails to the authors of the studies to obtain these data,
but none of them replied to our request. Therefore, we
excluded these studies from the meta-analysis (Babusa
&Túry, 2012; Babusa, Urban, Czeglédi, & Túry, 2012;
Guidi, Clementi, & Grandi, 2013; Hale et al., 2013;
Hildebrandt, Langenbucher, Karmin, Loeg, & Hollander,
2011; Hildebrandt et al., 2006; Hildebrandt, Walker, Alfano,
Delinsky, & Bannon, 2010; Kanayama, Barry, Hudson, &
Pope, 2006; Magallares, 2016). Thus, the meta-analysis
included 30 published articles; all of these studies were
published in a peer-reviewed journal between 2000
(Olivardia et al., 2000) and 2018 (Klimek, Murray, Brown,
Gonzales, & Blashill, 2018). Three of the 30 articles
provided data on four, two, and three independent samples,
respectively (Giardino & Procidano, 2012; Lamanna,
Grieve, Derryberry, Hakman, & McClure, 2010; Segura
García et al., 2010). Thus, the data set for our meta-analysis
was composed of a total of 36 independent samples.
Study characteristics
Appendix B presents descriptive characteristics of the arti-
cles included (n= 39) in the systematic review, yielding a
total of 45 studies or independent samples. Overall, the
majority of the studies used a convenience sample
(e.g., gymnasiums, vitamin stores, bodybuilding discussion
forums, Facebook, and university) and a cross-sectional
design. Only one study used a probabilistic sample
(Castro-Lopez, Cacho´n-Zagalaz, Molero, & Zagalaz-
Sánchez, 2013). A large number of studies were conducted
in the USA (n= 23), with 14 carried out in Europe, 4 in
Australia, and 2 in Mexico; one was conducted in China,
and a multinational was study carried out in the UK, the
USA, Australia, and Singapore.
The 45 independent samples included 8,516 participants
(mean= 189, range= 11, and 648 participants). The weight-
ed mean age of all participants was 25.89 years. Of the 45
independent samples, 31 were composed exclusively of men
and 7 of women, whereas both males and females
participated in the remaining 7 samples. Overall, the major-
ity of the participants was Caucasian, with the presence of
varying percentages of other racial and ethnic groups.
Finally, the majority of the participants had received at
least some college education.
The studies used a variety of instruments to measure MD
and ED. The tools most commonly used to assess MD were
the MDDI (Hildebrandt et al., 2004; n= 16), the MDI (Rhea
et al., 2004; n= 7), and the MASS (Mayville et al., 2002;
n= 11). The assessment instruments most frequently used in
the ED studies were the EAT-26 (Garner et al., 1982; n= 15),
the EDI (Garner et al., 1983; n= 12), and the EDE-Q
(Fairburn & Beglin, 1994; n= 10).
Assessment of methodological quality
Appendix C presents the results obtained from the assess-
ment of the methodological quality of the studies. Speciﬁ-
cally, the appendix shows the scores of individual studies on
each quality item. The researchers also obtained a TQS by
adding up the 1s and 0s for the checklist items (range =
0–10). On average, the studies had a methodological quality
of 5.28 (SD = 1.22), with a range of 3–7 points.
Most of the studies met the following criteria: (a) they
used participant’s samples that allowed an appropriate
representation of a clinical or at-risk MD or ED population
(n= 31); (b) they employed measurement instruments with
good psychometric properties (validity and reliability) to
assess MD in the study sample (n= 30); (c) they employed
measurement instruments with good psychometric proper-
ties (validity and reliability) to assess ED in the study
sample (n= 28); (d) they did not dichotomize the assess-
ment of MD and ED (n= 39); (e) they reported on results
related to all the MD and ED instruments described in
“Methods” section (n= 44); (f) they applied appropriate
statistical tests (non-parametric vs. parametric methods) to
assess the relationships between MD and ED (n= 24); and
(g) they had no private ﬁnancial support (n= 39). Never-
theless, most of the studies did not provide data on power
analysis or report CIs around the effect sizes measured.
Finally, the following criteria were least likely to be met
by the studies: (a) use of representative sampling procedures
(n= 1) and (b) a priori determination of the sample size to
identify an effect (n= 2). In addition, none of the studies
speciﬁed whether there were dropouts or if these dropouts
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had similar sociodemographic characteristics to those of the
ﬁnal sample.
Synthesis of results
This meta-analysis estimated the relationship between MD
and ED symptomatology. Figure 2 presents a forest plot of
the MD–ED associations found in each individual study and
their 95% CIs, as well as the mean correlation coefﬁcient
resulting from pooling all the studies and its corresponding
95% CI.
As Figure 2 shows, the pooled effect size for the
relationship between MD and ED was r+ = .356 (95%
CI= 0.298, 0.411, κ= 36). In addition, the analysis found
considerable heterogeneity among individual effect sizes,
[Q(35)= 200.925, p< .0001, I2 = 82.7%].
Analysis of publication bias
Because all the studies included were published papers, we
carried out analyses to determine whether publication bias
might be a threat to the validity of the results of the
meta-analysis. The Duval and Tweedie (2000) trim-and-ﬁll
method did not impute any effect size (see Appendix D). In
addition, the Egger’s test applied to the intercept of a simple
regression model of the effect sizes did not reach statistical
signiﬁcance [intercept = 1.09, t(34) = 1.176, p= .248].
Therefore, we can reasonably rule out publication bias as
a serious threat to our meta-analytic ﬁndings.
Moderator analyses of the relationships between MD and
ED symptomatology
The effect sizes showed a large amount of heterogeneity
(I2= 82.7%). Consequently, the researchers conducted sta-
tistical analyses to identify the study characteristics that
might explain this heterogeneity. Speciﬁcally, we used
weighted ANOVAs and simple meta-regressions for cate-
gorical and continuous moderator variables, respectively,
taking the correlation coefﬁcients between MD and ED
symptomatology as the dependent variable.
Table 1 presents the results of the ANOVAs conducted
on the categorical variables, such as country of the study,
type of sample, MD and ED measurement instrument, and
type of statistics reported. Three moderator variables
showed a statistically signiﬁcant association with effect
sizes: (a) the type of sample used in the study, (b) the
measurement instrument used to assess MD, and (c) the
measurement instrument used to assess ED. The type of
sample used in the study, classiﬁed as people who reported
current AAS use versus other samples, accounted for 26% of
the variance (p< .001). Speciﬁcally, a study found stronger
MD–ED associations when it was conducted among people
who used AAS (r+ = .710), compared to other samples
(r+ = .342). In addition, the tools used to assess ED
explained 26% of the variance (p< .001), with stronger
MD–ED associations found when the EDE-Q Modiﬁed was
the instrument used to assess ED (r+ = .642), in comparison
with other instruments (r+ = .336). Finally, studies that used
Study name Statistics for each study Correlation and 95% CI
Lower Upper 
Correlation limit limit Z-Value p-Value
Baile et al. (2011) .447 0.367 0.521 9.798 .000
Bo et al. (2014) .170 0.078 0.259 3.589 .000
Brown et al. (2017) .461 0.284 0.608 4.730 .000
Cafri et al. (2008) .059 -0.220 0.329 0.409 .682
Castro-Lopez et al. (2013) .280 0.127 0.420 3.535 .000
De Santis et al. (2012) .402 0.223 0.555 4.196 .000
Dryer et al. (2016) .363 0.219 0.491 4.735 .000
Giardiono & Procidano (2012) Sample1 .510 0.213 0.721 3.183 .001
Giardiono & Procidano (2012) Sample2 .420 -0.240 0.815 1.266 .205
Giardiono & Procidano (2012) Sample3 .500 0.235 0.696 3.474 .001
Giardiono & Procidano (2012) Sample4 .580 0.231 0.797 3.036 .002
Goodale et al. (2001) .546 0.465 0.618 10.960 .000
Hildebrandt et al. (2012) .180 0.043 0.311 2.561 .010
Hildebrandt et al. (2004) .496 0.393 0.586 8.321 .000
Hughes et al. (2016) .329 0.221 0.429 5.728 .000
Jin et al. (2015) .156 0.076 0.234 3.817 .000
Klimek et al. (2018) .570 0.462 0.661 8.615 .000
Lamanna et al. (2010) Sample1 .227 0.024 0.412 2.192 .028
Lamanna et al. (2010) Sample2 .467 0.303 0.604 5.138 .000
Latorre-Román et al. (2015) .422 0.245 0.572 4.410 .000
Lopez et al. (2015) .155 -0.025 0.325 1.690 .091
Maida & Amstrong (2005) .183 -0.008 0.361 1.878 .060
McFarland & Kaminski (2009) .135 0.017 0.249 2.244 .025
Mitchell et al. (2017) .310 0.061 0.523 2.420 .016
Murray et al. (2016) .710 0.609 0.788 9.678 .000
Murray et al. (2012) .539 0.330 0.697 4.551 .000
Nieuwoudt et al. (2015) .411 0.345 0.473 11.094 .000
Olivardia et al. (2000) .490 0.256 0.670 3.828 .000
Pope et al. (2005) .272 0.026 0.487 2.161 .031
Rhea et al. (2004) .460 0.324 0.577 6.050 .000
Santarnecchi & Dèttore (2012) .330 0.193 0.454 4.561 .000
Segura-García et al. (2010). Sample 1 .183 -0.030 0.380 1.686 .092
Segura-García et al. (2010). Sample 2 .251 -0.036 0.500 1.721 .085
Segura-García et al. (2010). Sample 3 .271 -0.195 0.637 1.146 .252
Sladek et al. (2014) .221 0.042 0.386 2.410 .016
Walker et al. (2009) .167 0.085 0.247 3.943 .000
.356 0.298 0.411 11.259 .000
-1.00 -0.50 0.00 0.50 1.00
Negative r Positive r
Figure 2. Forest plot of the association between MD and ED symptomatology
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quantitative measurement instruments to assess ED symp-
tomatology, such as EDE-Q or EAT, that had a larger mean
effect size (r+ = .364) than the studies that used other
instruments (r+ = .177), although this difference was only
marginally statistically signiﬁcant (p= .077, R2 = .01).
Table 2 presents the simple meta-regressions conducted
on continuous variables, such as mean age, gender
(% male), and ethnicity (% Caucasian) of the sample, as
well as the methodological TQS. The only moderator vari-
able that exhibited a statistically signiﬁcant association with
effect sizes was the methodological TQS for the individual
studies, accounting for 25% of the variance (p< .05).
In addition, in order to identify the individual items on
the quality checklist that were statistically associated with
Table 1. Results of the weighted ANOVAs for the inﬂuence of categorical variables on the effect sizes
Moderator variable k r+
95% CI
ANOVA resultsrl ru
Geographic location QB(1)= 0.051, p= .821
USA 18 .363 .274 .445 R2= .00
Other countries 18 .349 .270 .424 QW(34)= 195.879, p< .001
Sample setting
Gymnasiums 18 .359 .284 .430 QB(5)= 31.793, p< .001
University 9 .301 .169 .423 R2= .18
Area metropolitan 3 .352 .276 .425 QW(30)= 153.370, p< .001
AAS users 1 .710 .609 .788
Clinical (BDD or EDS) 2 .272 .055 .464
University and other 3 .387 .240 .516
Sample setting QB(1)= 30.137, p< .001
AAS users 1 .710 .609 .788 R2= .26
Other 35 .342 .287 .394 QW(34)= 167.137, p< .001
MD measurement
MDDI 12 .396 .278 .503 QB(7)= 17.087, p= .017
MASS 7 .367 .220 .497 R2= .00
SCID 3 .285 .031 .504 QW(28)= 171.339, p< .001
ACQ 4 .398 .320 .471
MDS 1 .135 .017 .249
MDI 6 .293 .185 .394
MDQ 1 .363 .219 .491
MDSQ 2 .386 −.012 .678
Type of MD measurement QB(1)= 0.385, p= .535
Diagnostic 3 .285 .031 .504 R2= .00
Symptomatology 33 +.361 .301 .419 QW(34)= 202.228, p< .001
ED measurementa
EAT 14 .345 .263 .423 QB(6)= 30.585, p< .001
EDI 10 .348 .268 .423 R2= .23
EDE-Q 7 .348 .187 .491 QW(30)= 141.207, p< .001
EDE-Q Modiﬁed 2 .642 .449 .777
SCID 2 .177 −.036 .374
MEBBIE 1 .135 .017 .249
CHAA 1 .447 .367 .521
EDQ Modiﬁed vs. othersa QB(1)= 8.087, p= .007
EDE-Q Modiﬁed 2 .642 .449 .777 R2= .26
Others 35 .336 .281 .389 QW(35)= 167.335, p< .001
Type of ED measurementa QB(1)= 3.129, p= .077
Diagnostic 2 .177 −.036 .374 R2= .01
Symptomatology 35 .364 .305 .419 QW(35)= 200.840, p< .001
Statistics reported QB(1)= 2.274, p= .132
Correlation coefﬁcient 32 .368 .308 .426 R2= .03
Odds ratio 4 .242 .078 .393 QW(34)= 189.439, p< .001
Note. k: number of studies. r+: mean effect size. rl and ru: 95% lower and upper conﬁdence limits around r+; QB: between-categories Q
statistic; QW: within-categories Q statistic; R
2: proportion of variance accounted for by the moderator variable; ED: eating disorder; EDE-Q:
Eating Disorder Examination Questionnaire; MEBBIE: Male Eating Behavior and Body Image Evaluation; CHAA: Cuestionario de Hábitos
de Alimentacio´n Alterados; SCID: structured clinical Interview for DSM-IV; MDDI: Muscle Dysmorphic Disorder Inventory; MASS:
Muscle Appearance Satisfaction Scale; MDI: Muscle Dysmorphia Inventory; AAS: anabolic androgenic steroid; ACQ: Adonis Complex
Questionnaire; MDSQ: Muscle Dysmorphia Symptom Questionnaire; MDQ: Muscle Dysmorphia Questionnaire; CI: conﬁdence interval;
ANOVA: analysis of variance; BDD: body dysmorphic disorder.
aHughes et al.’s (2016) study used two tools for assessing EDs (EAT-26 and EDEQ).
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the effect sizes, we applied ANOVAs for each individual
item (see Table 3). As Table 3 shows, items 4, 5, and 6 were
statistically associated with the effect sizes. Thus, studies
that reported any estimate of the reliability/validity of the
MD measurement instrument (item 4) or any estimate of the
reliability/validity of the ED measurement used in the study
sample (item 5) showed a mean effect size (r+ = .403 and
r+ = .416, respectively) larger than those that did not
(r+ = .255 and r+ = .196, respectively), accounting for a
large proportion of variance (R2 = .13 and R2= .31,
respectively). In addition, studies that did not dichotomize
MD and/or ED variables showed a mean effect size
(r+ = .376) larger than those that did so (r+ = .219),
accounting for a moderate proportion of variance (R2= .06).
DISCUSSION
This is the ﬁrst meta-analytic study on the relationship
between MD and ED symptomatology. Our results showed
that there is a positive and statistically signiﬁcant relation-
ship between MD and ED symptomatology, indicating that
higher levels of MD were associated with higher levels of
ED symptomatology. Following Cohen’s (1988) criteria, a
correlation coefﬁcient of r+ = .356 can be interpreted as
reﬂecting a relationship of moderate magnitude. Our ﬁnd-
ings are consistent with the ﬁndings from Tod and
Edwards’s (2015b) review, which found an association
between DFM and ED symptomatology. However, the
strength of the correlation was greater between MD and
Table 2. Results of the simple weighted meta-regressions of continuous moderators on the effect sizes
Moderator variable k bj QR QE R
2
Mean age (years) 36 0.0015 0.05 196.51** .0
Gender (% males) 36 0.0000 0.45 199.26** .0
Ethnicity (% Caucasian) 19 −0.0003 0.03 101.58** .0
Methodology quality checklist (0–10) 36 0.0776 10.03* 176.31** .25
Note. k: number of studies; bj: unstandardized regression coefﬁcient; QR: Q statistic for testing the statistical signiﬁcance of the moderator
variable; QE: Q statistic for testing the model misspeciﬁcation; R
2: proportion of variance accounted for by the moderator variable.
*p< .05. **p< .001.
Table 3. Results of the weighted ANOVAs for the inﬂuence of methodological quality items on the effect sizes
Quality item k r+
95% CI
ANOVA resultsrl ru
1. Probabilistic sampling QB(1)= 0.988, p= .320
Yes 1 .280 .127 .420 R2= .00
No 35 .359 .299 .415 QW(34)= 202.124, p< .001
2. Adequate target population QB(1)= 1.118, p= .290
Yes 24 .380 .310 .446 R2= .01
No 12 .316 .215 .411 QW(34)= 191.814, p< .001
4. Reliability/validity MD measurement tool QB(1)= 6.928, p= .008
Yes 24 .403 .331 .470 R2= .13
No 12 .255 .167 .339 QW(34)= 192.883, p< .001
5. Reliability/validity ED measurement tool QB(1)= 26.172, p< .001
Yes 24 .416 .349 .479 R2= .31
No 12 .196 .147 .244 QW(34)= 159.323, p< .001
6. Absence of dichotomous DM and ED QB(1)= 6.412, p= .011
Yes 30 .376 .314 .434 R2= .06
No 6 .219 .109 .324 QW(34)= 186.515, p< .001
8. Statistical test appropriate QB(1)= 0.058, p= .810
Yes 21 .360 .280 .435 R2= .00
No 15 .346 .265 .423 QW(34)= 202.325, p< .001
9. Private ﬁnancial support QB(1)= 0.138, p= .711
Yes 4 .373 .288 .452 R2= .00
No 32 .354 .290 .414 QW(34)= 201.692, p< .001
10. Statistical power QB(1)= 0.426, p= .514
Yes 2 .251 −.101 .548 R2= .00
No 34 .361 .302 .418 QW(34)= 202.397, p< .001
Note. Results for item 3 (dropouts were similar in socio-demographic characteristics to those of the ﬁnal sample) and item 7 (absence of
reporting bias) were not analyzed because all studies scored 0 and 1, respectively. k: number of studies; r+: mean effect size; rl and ru: 95%
lower and upper conﬁdence limits around r+;QB: between-categoriesQ statistic;QW: within-categories Q statistic; R
2: proportion of variance
accounted for by the moderator variable; ANOVA: analysis of variance; ED: eating disorder; MD: muscle dysmorphia.
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ED symptomatology (r= .36) than between DFM and ED
(r= .27). These ﬁndings suggest that both MD and DFM
share an association with EDs. People with DFM and MD
want to gain lean muscle mass, which is achieved not only
through physical training but also by maintaining a diet high
in lean protein and using food supplements. Therefore,
dietary practices are an important factor in both DFM and
MD. Furthermore, research suggests that the behavior and
diet subscales of the DFM predict MD characteristics
(Robert et al., 2009), which might explain that both MD
and DFM share an association with EDs. In other research,
DFM has been identiﬁed as a precursor to the development
of MD (Olivardia et al., 2000). Therefore, those who scored
high on a measure of MD displayed a higher degree of
DFM. From this point of view, MD might be considered an
extreme variant of DFM.
We ruled out publication bias as a threat to our meta-
analytic results, but we found great variability among the
individual effect sizes. In order to identify the study features
that could explain at least part of the effect size variability,
we carried out ANOVAs and meta-regressions. Several
study characteristics were statistically related to effect size,
such as the type of sample, the methodological quality, and
the MD and ED measurement instruments used. First, our
ﬁndings showed stronger associations between MD and ED
symptomatology in males reporting current AAS use than in
other people (undergraduates, athletes, etc.). However, this
result must be interpreted very cautiously because AAS
samples were represented in only one study. Therefore, it
seems plausible that males who use AAS exhibit elevated
levels of MD symptomatology. Indeed, some of the most
common motivations for using AAS are to increase muscle
mass and strength (Cohen, Collins, Darkes, & Gwartney,
2007), to improve physical appearance (Kimergård, 2015),
and to decrease body dissatisfaction and MD symptoms
(Grogan, Shepherd, Evans, Wright, & Hunter, 2006). In this
way, research has identiﬁed MD symptoms as a predictor of
the use of substances such as anabolic steroids, prohor-
mones, and ephedrine (Cafri, van den Berg, & Thompson,
2006). Thus, people who use AAS might be at greater risk of
developing MD and ED symptomatology. These ﬁndings
suggest the need to implement health promotion and
prevention programs to reduce AAS use.
Furthermore, our results showed that of all the ED
measurement instruments, the EDE-Q Modiﬁed (Murray
et al., 2012) was the most sensitive tool in identifying
relationships with MD symptomatology. Some conceptual
overlapping between the EDE-QModiﬁed and the measures
of MD is likely. It is important to note that the EDE-Q
Modiﬁed is a version of the EDE-Q with the gender-relevant
items identiﬁed and reversed in polarity to enhance its
sensitivity in indexing male concerns (Murray et al.,
2012). For instance, the item on the EDE-Q “Have you
had a deﬁnite fear that you might gain weight or become
fat?” was reversed on the EDE-Q Modiﬁed to “Have you
had a deﬁnite fear that you might lose weight or become less
muscular?”Other examples of reversed items are “Have you
been deliberately trying to increase the amount of food you
eat to inﬂuence your shape or weight?” and “Has thinking
about food or its protein content made it more difﬁcult to
concentrate on things you are interested in; for example,
reading, watching TV, or following a conversation?” (mod-
iﬁcations italicized). Such overlaps might inﬂuence the
strength of the relationships between MD and ED symp-
tomatology. In addition, it is plausible that the strength of
the association between MD and the EDE-QModiﬁed might
be affected by the type of sample used to examine this
relationship. In this regard, the only two studies that applied
the EDE-Q Modiﬁed (Murray, Grifﬁths, Mond, Kean, &
Blashill, 2016; Murray et al., 2012) used samples of parti-
cipants who were not from a community population. In one
of them; the participants were AAS users (Murray et al.,
2016), and in the other study, they were clinical participants
(Murray et al., 2012). Therefore, clinicians should be aware
of this fact and take it into account when identifying co-
occurrence.
Moreover, our ﬁndings revealed that of all the ED
assessment instruments, the SCID was the least sensitive
in identifying relationships between MD and ED symptom-
atology, which might explain why the study by Cafri et al.
(2008) did not reveal a relationship between MD and ED
symptomatology. One possible explanation is that the SCID
provides a more thorough and conservative assessment of an
ED, having less overlap with MD than other ED measures.
This might suggest that MD is associated with certain ED
symptoms but not strongly or consistently with a separate
ED diagnosis.
Finally, our ﬁndings suggest that studies with higher
methodological quality are more sensitive in identifying
relationships between MD and ED symptomatology. In
addition, we found stronger MD–ED associations in the
studies that assessed the psychometric properties of the MD
and ED instruments with the data found than in those that
did not assess these properties. These results agree with
psychometric theory, which proposes that using measure-
ment instruments with good psychometric properties will
provide greater sensitivity in revealing statistical associa-
tions between variables than using non-reliable and/or
non-valid instruments. Finally, we found lower MD–ED
associations in the studies that dichotomized the MD and
ED measures (i.e., reporting ORs instead of Pearson’s
correlation coefﬁcients). These results agree with statistical
theory, which proposes that dichotomizing variables pro-
duce a loss of sensitivity in detecting statistical associations
among variables (Schmidt & Hunter, 2015). Therefore, one
would expect higher correlations in studies with higher
methodological quality that used quantitative measurement
instruments for MD assessment, such as MASS and MDDI,
and for ED assessment, such as EAT or EDE-Q.
Limitations
This meta-analysis has several limitations. Five studies
could not be included in the ﬁnal analysis because the
statistical data reported did not allow us to calculate the
effect sizes, and their authors did not reply to the request for
data. Furthermore, most of the studies included were con-
ducted in the USA, which might limit the generalization of
the results. In addition, given the existence of great
heterogeneity among the effect sizes, it is possible that
other moderator variables not considered in our meta-
analysis might be relevant in explaining this heterogeneity
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(Menees, Grieve, Mienaltowski, & Pope, 2013). These
moderators are likely to be psychosocial constructs
such as socially prescribed perfectionism (Dryer, Farr,
Hiramatsu, & Quinton, 2016) or masculinity-related
constructs (Tod et al., 2016). Increased understanding and
awareness of MD and ED symptomatology might contribute
to identifying and referring people at risk, so that they can
receive help from mental health services. Finally, it is
important to remember that all the studies included in this
meta-analysis were cross-sectional, which means we cannot
draw causal inferences about the relationship between MD
and ED symptomatology.
Recommendations for future research
Most research on MD–ED has used non-clinical samples,
often university students, who, in general, have low
psychopathology. Thus, future research should investigate
the MD–ED association in clinical samples, that is, in
people diagnosed with MD and/or ED. These studies might
improve our knowledge to develop more optimal treatment
approaches. On other hand, to ﬁnd out whether the EDE-Q
Modiﬁed (Murray et al., 2012) is really the most sensitive
tool for assessing the association between MD and ED
symptomatology, additional studies are needed to analyze
this relationship in community samples.
Moreover, given that most of the studies used cross-
sectional designs, which do not allow us to draw causal
inferences about the relationship between MD and ED
symptomatology, future research should implement
longitudinal studies. These studies might help to clarify the
relationship between MD and ED symptomatology in
chronological terms, for instance, whether ED precedes MD
or vice versa, and they might clarify the stability of MD and/
or ED symptomatology.
Finally, given that most of the studies were conducted in
the USA and with male participants, future research should
study this topic in other social contexts and in the female
population in order to investigate potential differences based
on cultural factors and/or sex differences.
CONCLUSIONS
This is the ﬁrst meta-analytic study on the relationship
between MD and ED symptomatology, contributing to a
more accurate view of this phenomenon, despite the limita-
tions described above. Furthermore, our ﬁndings may have
some implications for clinical practice. They suggest that the
symptoms and behaviors characteristic of MD tend to
co-occur with ED symptomatology in males and females.
Thus, when evaluating individuals presenting with MD,
clinicians should investigate the possibility of the presence
of ED, and vice versa, particularly in males. In this regard, a
recent case study showed the transition from thinness-
oriented to muscularity-oriented disordered eating during
the course of treatment for AN (Murray, Grifﬁths,
Mitchison, & Mond, 2017). As the authors of this study
pointed out, the emergence of muscularity-oriented
disordered eating during the treatment of AN might be
misinterpreted as healthy, due to the move away from
dangerously low body weight, which is the objective of
AN treatment.
People with MD symptomatology may also have ED
symptomatology, which appears to be associated with
greater psychopathology (Chandler, Grieve, Derryberry, &
Pegg, 2009; Ebbeck, Watkins, Concepcion, Cardinal, &
Hammermeister, 2009; Grieve & Shacklette, 2012; Pope
et al., 2005). This situation, in addition to the serious
limitations in social and work performance caused by MD
and the associated unhealthy behaviors, makes it necessary
to use strategies for identifying at-risk individuals and for
prevention, such as inviting them to participate in
psychotherapy. Because MD and ED symptomatology, and
the co-occurrence of these symptoms, can occur more often
among athletes, the development of such intervention strat-
egies may be of special interest for mental health profes-
sionals working in the sports area. We do not believe that
participation in sports is inherently pathological, but it is
likely that some individuals take up sports for reasons
(which may be pathological) that correlate with MD and
ED symptomatology or increase the risk of developing
symptoms of these two disorders. A psychological assess-
ment conducted by an experienced sports psychologist
could identify the athletes in need of psychological treat-
ment. Based on our data, we recommend that clinicians use
the MDDI or MASS to assess MD and the EDE-Q Modiﬁed
to assess ED when examining the co-occurrence of MD and
ED symptomatology. These are the most sensitive measure-
ment instruments in identifying relationships between MD
and ED (considering the previous discussion about the
EDEQ Modiﬁed).
Funding sources: This research is not funded by a speciﬁc
project grant.
Authors’ contribution: CL and MAF conceived of the
presented idea and developed the theory. LB-R and
MR-A performed the computations and statistical analysis.
JS-M veriﬁed the analytical methods and supervised the
ﬁndings of this work. All authors discussed the results and
contributed to the ﬁnal manuscript.
Conﬂict of interest: The authors declare no potential conﬂict
of interest with regard to the research, authorship, and/or
publication of this article.
REFERENCES
References marked with an asterisk indicate studies included in the
meta-analysis.
American Psychiatric Association [APA]. (2013). Diagnostic and
statistical manual of mental disorders (DSM-5). Washington,
DC: American Psychiatric Association.
Appelbaum, M., Cooper, H., Kline, R. B., Mayo-Wilson, E., Nezu,
A. M., & Rao, S. M. (2018). Journal article reporting standards
for quantitative research in psychology: The APA Publications
and Communications Board Task Force report. American
Psychologist, 73(1), 3–25. doi:10.1037/amp0000191
360 | Journal of Behavioral Addictions 8(3), pp. 351–371 (2019)
Badenes-Ribera et al.
*Babusa, B., & Túry, F. (2012). Muscle dysmorphia in Hungarian
non-competitive male bodybuilders. Eating Weight Disorders,
17, e49–e53. doi:10.1007/BF03325327
*Babusa, B., Urbán, R., Czeglédi, E., & Túry, F. (2012).
Psychometric properties and construct validity of the Muscle
Appearance Satisfaction Scale among Hungarian men. Body
Image, 9(1), 155–162. doi:10.1016/j.bodyim.2011.08.005
*Baile, J. I., González, A., Ramírez, C., & Suárez, P. (2011).
Imagen corporal, hábitos alimentarios y hábitos de ejercicio
físico en hombres usuarios de gimnasio y hombres
universitarios no usuarios [Body image, eating behaviours and
exercise training among male gym users and male non-users at
the university]. Revista de Psicología del Deporte,
20, 353–366. Retrieved from http://www.rpd-online.com/
article/view/783
*Bo, S., Zoccali, R., Ponzo, V., Soldati, L., De Carli, L., Benso, A.,
Fea, E., Rainoldi, A., Durazzo, M., Fassino, S., &
Abbate-Daga, G. (2014). University courses, eating problems
and muscle dysmorphia: Are there any associations? Journal of
Translational Medicine, 12, 221. doi:10.1186/s12967-014-
0221-2
Borenstein, M. J, Hedges, L. V., Higgins, J. P., & Rothstein, H. R.
(2009). Introduction to meta-analysis. Chichester, UK: Wiley.
Borenstein, M. J., Hedges, L. V., Higgins, J., & Rothstein, H. R.
(2014). Comprehensive meta-analysis (version 3). Englewood,
NJ: Biostat.
*Brown, T. A., Forney, K. J., Pinner, D., & Keel, P. K. (2017). A
randomized controlled trial of The Body Project: More Than
Muscles for men with body dissatisfaction. International
Journal of Eating Disorders, 50, 873–883. doi:10.1002/
eat.22724
*Cafri, G., Olivardia, R., & Thompson, J. K. (2008). Symptom
characteristics and psychiatric comorbidity among males with
muscle dysmorphia. Comprehensive Psychiatry, 49, 374–379.
doi:10.1016/j.comppsych.2008.01.003
Cafri, G., Thompson, J. K., Ricciardelli, L., McCabe, M., Smolak,
L., & Yesalis, C. (2005). Pursuit if the muscular ideal: Physical
and psychological consequences and putative risk factors.
Clinical Psychology Review, 25(2), 215–239. doi:10.1016/j.
cpr.2004.09.003
Cafri, G., van den Berg, P., & Thompson, J. K. (2006). Pursuit of
muscularity in adolescent boys: Relations among biopsycho-
social variables and clinical outcomes. Journal of Clinical
Child and Adolescent Psychology, 35(2), 283–291.
doi:10.1207/s15374424jccp3502_12
*Castro-Lopez, R., Cacho´n-Zagalaz, J., Molero, D., &
Zagalaz-Sánchez, M. L. (2013) Dismorﬁa muscular y su
relacio´n con síntomas de trastornos de la conducta alimentaria
[Muscle dysmorphia and its relationship with the symptoms of
eating disorders]. Revista Mexicana de Trastornos Alimentarios
[Mexican Journal of Eating Disorders], 4, 31–36. Retrieved
from http://www.scielo.org.mx/scielo.php?script=sci_arttext&
pid=S2007-15232013000100004&lng=es
Cella, S., Iannaccone, M., & Cotrufo, P. (2012). Muscle dysmor-
phia: A comparison between competitive bodybuilders and
ﬁtness practitioners. Journal of Nutritional Therapeutics, 1,
12–18. Retrieved from http://www.lifescienceglobal.com/pms/
index.php/jnt/article/view/451/pdf
Chandler, C. G., Grieve, F. G., Derryberry, W. P., & Pegg, P. O.
(2009). Are anxiety and obsessive-compulsive symptoms
related to muscle dysmorphia? International Journal of Men’s
Health, 8, 143–154. Retrieved from http://www.mensstudies.
info/OJS/index.php/IJMH/article/view/568
Chaney, M. P. (2008). Muscle dysmorphia, self-esteem, and
loneliness among gay and bisexual men. International Journal
of Men’s Health, 7(2), 157–170. doi:10.3149/jmh.0702.157
Choi, P. Y. L., Pope, H., & Olivardia, R. (2002). Muscle dysmor-
phia: A new syndrome in weightlifters. British Journal of
Sports Medicine, 36(5), 375–376. doi:10.1136/bjsm.36.5.375
Cohen, J. (1988). Statistical power analysis for the behavioral
sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
Cohen, J., Collins, R., Darkes, J., & Gwartney, D. (2007). A league
of their own: Demographics, motivations and patterns of use of
1,955 male adult non-medical anabolic steroid users in the
United States. Journal of the International Society of Sports
Nutrition, 4(1), 12. doi:10.1186/1550-2783-4-12
Cubberley, R. (2009). Evaluating the reliability and validity of the
Muscle Dysmorphia Inventory (Master’s thesis). Western
Kentucky University, Bowling Green, Kentucky. Retrieved
from http://digitalcommons.wku.edu/theses/121/
*De Santis, J. P., Layerla, D. M., Barroso, S., Gattamorta, K. A.,
Sanchez, M., & Prado, G. J. (2011). Predictors of eating attitudes
and behaviors among gay Hispanic men. Archives of Psychiatric
Nursing, 26, 11–126. doi:10.1016/j.apnu.2011.06.003
Dos Santos, C. A., Tirico, P. P., Stefano, S. C., Touyz, S. W., &
Claudino, A. M. (2015). Systematic review of the diagnostic
category muscle dysmorphia. Australian and New Zealand
Journal of Psychiatry, 50(4), 322–333. doi:10.1177/
0004867415614106
*Dryer, R., Farr, M., Hiramatsu, I., & Quinton, S. (2016). The role
of sociocultural inﬂuences on symptoms of muscle dysmorphia
and eating disorders in men, and the mediating effects of
perfectionism. Behavioral Medicine, 42(3), 174–182.
doi:10.1080/08964289.2015.1122570
Duval, S., & Tweedie, R. (2000). Trim and ﬁll: A simple funnel-
plot- based method of testing and adjusting for publication bias
in meta-analysis. Biometrics, 56(2), 455–463. doi:10.1111/
j.0006-341X.2000.00455.x
Ebbeck, V., Watkins, P. L., Concepcion, R. Y., Cardinal, B. J., &
Hammermeister, J. (2009). Muscle dysmorphia symptoms and
their relationships to self-concept and negative affect among
college recreational exercisers. Journal of Applied Sport Psy-
chology, 21(3), 262–275. doi:10.1080/10413200903019376
Fabris, M. A., Longobardi, C., Prino, L. E., & Settani, M. (2017).
Attachment style and risk of muscle dysmorphia in a sample of
male bodybuilders. Psychology of Men & Masculinity, 19(2),
273–281. doi:10.1037/men0000096
Fairburn, C. G., & Beglin, S. J. (1994). Assessment of eating
disorders: Interview or self-report questionnaire? International
Journal of Eating Disorders, 16(4), 363–370. doi:10.1002/1098-
108X(199412)16:4<363::AID-EAT2260160405>3.0.CO;2-%23
Garner, D. M., Olmstead, M. P., Bohr, Y., & Garﬁnkel, P. E.
(1982). The Eating Attitudes Test: Psychometric features and
clinical correlates. Psychological Medicine, 12(4), 871–878.
doi:10.1017/S0033291700049163
Garner, D., Olmstead, M. P., & Polivy, J. (1983). Development and
validation of a Multidimensional Eating Disorder Inventory for
anorexia nervosa and bulimia. International Journal of Eating
Disorders, 2(2), 15–34. doi:10.1002/1098-108X(198321)
2:2<15::AID-EAT2260020203>3.0.CO;2-6
*Giardino, J. C., & Procidano, M. E. (2012). Muscle dysmorphia
symptomatology: A cross-cultural study in Mexico and the
Journal of Behavioral Addictions 8(3), pp. 351–371 (2019) | 361
Muscle dysmorphia and eating disorders
United States. International Journal of Men’s Health, 11(1),
83–103. doi:10.3149/jmh.1101.83
*Goodale, K. R., Watkins, P. L., & Cardinal, B. J. (2001). Muscle
dysmorphia: A new form of eating disorder? American Journal
of Health Education, 32(5), 260–266. doi:10.1080/19325037.
2001.10603480
Grieve, F. G. (2007). A conceptual model of factors contributing to
the development of muscle dysmorphia. Eating Disorders,
15(1), 63–80. doi:10.1080/10640260601044535
Grieve, F. G., & Shacklette, M. D. (2012). Brief report on
men’s bodies and mood: Correlates between depressive
symptoms and muscle dysmorphia symptoms. North
American Journal of Psychology, 14, 563. Retrieved from
http://www.freepatentsonline.com/article/North-American-
Journal-Psychology/312401777.html
Grieve, F. G., Truba, N., &Bowersox, S. (2009). Etiology, assessment,
and treatment of muscle dysmorphia. Journal of Cognitive Psy-
chotherapy, 23(4), 306–314. doi:10.1891/0889-8391.23.4.306
Grifﬁths, S., Murray, S., & Touyz, S. (2013). Drive for muscularity
and muscularity-oriented disordered eating in men: The role of
set shifting difﬁculties and weak central coherence. Body
Image, 10(4), 636–639. doi:10.1016/j.bodyim.2013.04.002
Grogan, S., Shepherd, S., Evans, R., Wright, S., & Hunter, G.
(2006). Experiences of anabolic steroid use: In-depth inter-
views with men and women body builders. Journal of Health
Psychology, 11(6), 845–856. doi:10.1177/1359105306069080
*Guidi, J., Clementi, C., & Grandi, C. (2013). Valutazione del
disagio psicologico e delle caratteristiche di personalità nella
dipendenza da esercizio ﬁsico primaria [Psychological distress
and personality characteristics among individuals with primary
exercise dependence]. Rivista di Psichiatria, 48, 121–129.
doi:10.1708/1272.14036
Hale, W. D. (2008). Scale development in muscle dysmorphia
(Unpublished doctoral dissertation). Oklahoma State Univer-
sity, Stillwater, OK.
*Hale, B., Diehl, D., Weaver, K., & Briggs, M. (2013). Exercise
dependence and muscle dysmorphia in novice and experienced
female bodybuilders. Journal of Behavioral Addictions, 2(4),
244–248. doi:10.1556/JBA.2.2013.4.8
*Hildebrandt, T., Harty, S., & Langenbucher, J. W. (2012). Fitness
supplements as a gateway substance for anabolic-androgenic
steroid use. Psychology of Addictive Behaviors, 26(4),
955–962. doi:10.1037/a0027877
*Hildebrandt, T., Langenbucher, J. W., Karmin, J. K., Loeg, K. L., &
Hollander, E. (2011). Development and validation of Appearance
and Performance Enhancing Drug Use Schedule. Addictive
Behaviors, 36(10), 949–958. doi:10.1016/j.addbeh.2011.05.002
*Hildebrandt, T., Langenbucher, J., & Schlundt, D. G. (2004).
Muscularity concerns among men: Development of attitudinal
and perceptual measures. Body Image, 1(2), 169–181.
doi:10.1016/j.bodyim.2004.01.001
*Hildebrandt, T., Schlundt, D., Langenbucher, J., & Chung, T.
(2006). Presence of muscle dysmorphia symptomatology
among male weightlifters. Comprehensive Psychiatry, 47(2),
127–135. doi:10.1016/j.comppsych.2005.06.001
*Hildebrandt, T., Walker, C. D., Alfano, L., Delinsky, S., &
Bannon, K. (2010). Development and validation of a Male
Speciﬁc Body Checking Questionnaire. International Journal
of Eating Disorders, 43, 77–87. doi:10.1002/eat.20669
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., &
Botella, J. (2006). Assessing heterogeneity in meta-analysis: Q
statistic or I2 index? Psychological Methods, 11(2), 193–206.
doi:10.1037/1082-989X.11.2.193
*Hughes, E. K., Dean, C., & Allen, J. S. (2016). Measures of eating
disorder symptoms, drive for muscularity, and muscle
dysmorphia: Norms and typologies of Australian men. Australian
Journal of Psychology, 68(4), 270–280. doi:10.1111/ajpy.12105
*Jin, X., Jin, Y., Zhou, S., Li, X., Yang, S., Yang, D., Nieuwoudt,
J. E., & Yao, J. (2015). The Muscle Appearance Satisfaction
Scale: A factorial analysis of validity and reliability for its use
on adult Chinese male weightlifters. Body Image, 14, 94–101.
doi:10.1016/j.bodyim.2015.04.004
Kaminski, P. L., McFarland, M. B., & Chapman, B. P. (2008).
The Muscle Dysmorphia Scale (MDS). Available from the
author: Department of Psychology, University of North
Texas, Denton, TX.
Kaminski, P. L., Slaton, S. R., Caster, J., Own, L., Baker, K., &
Chapman, B. P. (2002, November). The Male Eating Behavior
and Body Image Evaluation (MEBBIE): A scale to measure
eating, exercise, and body image concerns in men. Poster
presented at the annual convention of the Texas Psychological
Association, San Antonio, TX.
*Kanayama, G., Barry, S., Hudson, J. I., & Pope, H. G. (2006).
Body image and attitudes toward male roles in anabolic-
androgenic steroid users. American Journal of Psychiatry,
163(4), 697–703. doi:10.1176/ajp.2006.163.4.697
Kimergård, A. (2015). A qualitative study of anabolic steroid use
amongst gym users in the United Kingdom: Motives, beliefs
and experiences. Journal of Substance Use, 20(4), 288–294.
doi:10.3109/14659891.2014.911977
Kimmel, S. B., & Mahalik, J. R. (2004). Measuring masculine
body ideal distress: Development of a measure. International
Journal of Men’s Health, 3(1), 1–10. doi:10.3149/jmh.
0301.1
Klimek, P., & Hildebrandt, T. (2018). Psychosocial correlates of gap
time to anabolic-androgenic steroid use. International Journal of
Eating Disorders, 51(6), 535–541. doi:10.1002/eat.22859
*Klimek, P., Murray, S. B., Brown, T., Gonzales, M., & Blashill,
A. J. (2018). Thinnes and muscularity internalization: Associa-
tions with disordered eating and muscle dysmorphia in men.
International Journal of Eating Disorders, 51(4), 352–357.
doi:10.1002/eat.22844
*Lamanna, J., Grieve, F. G., Derryberry, W. P., Hakman, M., &
McClure, A. (2010). Antecedents of eating disorders and
muscle dysmorphia in a non-clinical sample. Eating Weight
Disorders, 15(1-2), e23–e33. doi:10.1007/BF03325277
Lantz, C. D., Rhea, D. J., & Cornelius, A. E. (2002). Muscle
dysmorphia in elite-level power lifters and bodybuilders: A test
of differences within a conceptual model. Journal of Strength
and Conditioning Research, 16(4), 649e655. doi:10.1519/
00124278-200211000-00026
*Latorre-Román, P. A., Garrido-Ruiz, A., & García-Pinillos, F.
(2015). Versio´n espan˜ola del cuestionario del complejo de
Adonis: un cuestionario para el análisis del dimorﬁsmomuscular
o vigorexia [Spanish version of the Adonis Complex
Questionnaire: A questionnaire for the analysis of muscle
dysmorphia or bigorexia]. Nutricio´n Hospitalaria, 31,
1246–1253. doi:10.3305/nh.2015.31.3.8292
Lavender, J. M., Brown, T. A., & Murray, S. B. (2017).
Men, muscles, and eating disorders: An overview of traditional
and muscularity-oriented disordered eating. Current Psychia-
try Reports, 19(6), 32. doi:10.1007/s11920-017-0787-5
362 | Journal of Behavioral Addictions 8(3), pp. 351–371 (2019)
Badenes-Ribera et al.
Longobardi, C., Prino, L. E., Fabris, M. A., & Settani, M. (2017).
Muscle dysmorphia and psychopathology: Findings from an
Italian sample of male bodybuilders. Psychiatric Research,
256, 231–236. doi:10.1016/j.psychres.2017.06.065
*Lopez, A., Pollack, L., Gonzales, S., Pona, A. A., & Lundgren, J. D.
(2015). Psychosocial correlates of muscle dysmorphia among
collegiate males. Journal of Psychological Inquiry, 20, 58–66.
Lopez-Cuautle, C., Vazquez-Arevalo, R., & Mancilla-Diaz,
J. M. (2016). Evaluacio´n diagno´stica de la dismorﬁa mus-
cular [Diagnostic evaluation of muscular dysmorphia].
Anales de Psicología, 32(2), 405–4016. doi:10.6018/
analesps.32.2.203871
Lo´pez-Lo´pez, J. A., Marín-Martínez, F., Sánchez-Meca, J., van den
Noortgate, W., & Viechtbauer, W. (2014). Estimation of the
predictive power of the model in mixed-effects meta-regression:
A simulation study. British Journal of Mathematical and Sta-
tistical Psychology, 67(1), 30–48. doi:10.1111/bmsp.12002
*Magallares, A. (2016). Drive for thinness and pursuit of muscu-
larity: The role of gender ideologies.Universitas Psychologica,
15(2), 353–360. doi:10.11144/Javeriana.upsy15-2.dtpm
*Maida, D. M., & Armstrong, S. L. (2005). The classiﬁcation of
muscle dysmorphia. International Journal of Men’s Health,
4(1), 73–91. doi:10.3149/jmh.0401.73
Mayville, S. B., Williamson, D. A., White, M. A., Netemeyer,
R. G., & Drab, D. L. (2002). Development of the Muscle
Appearance Satisfaction Scale: A self-report measure for the
assessment of muscle dysmorphia symptoms. Assessment,
9(4), 351–360. doi:10.1177/1073191102238156
*McFarland, M. B., & Kaminski, P. L. (2009). Men, muscles and
mood: The relation between self-concept, dysphoria, and body
image disturbances. Eating Behaviors, 10(1), 68–70.
doi:10.1016/j.eatbeh.2008.10.007
Menees, L., Grieve, F. G., Mienaltowski, A., & Pope, J. (2013).
Critical comments about the body and muscle dysmorphia
symptoms in collegiate men. International Journal of Men’s
Health, 12(1), 17–28. doi:10.3149/jmh.1201.17
Mitchell, L., Murray, S. B., Cobley, S., Hackett, D., Gifford, J.,
Capling, L., & O’Connor, H. (2017). Muscle dysmorphia
symptomatology and associated psychological features in
bodybuilders and non-bodybuilder resistance trainers: A
systematic review and meta-analysis. Sports Medicine,
47(2), 233–259. doi:10.1007/s40279-016-0564-3
*Mitchell, L., Murray, S. B., Hoon, M., Hackett, D., Prvan, T., &
O’Connor, H. (2017). Correlates of muscle dysmorphia symp-
tomatology in natural bodybuilders: Distinguishing factors in
the pursuit of hyper-muscularity. Body Image, 22, 1–5.
doi:10.1016/j.bodyim.2017.04.003
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The
PRISMA Group. (2009). Preferred reporting items for
systematic reviews and meta-analyses: The PRISMA state-
ment. Annals of Internal Medicine, 151(4), 264–269.
doi:10.7326/0003-4819-151-4-200908180-00135
Morrison, T. G., Morrison, M. A., & McCann, L. (2006). Striving
for bodily perfection? An overview of the drive for musculari-
ty. In M. V. Kindes (Ed.), Body image: New research
(pp. 1–34). Hauppauge, NY: Nova Science.
Murray, S. B., Grifﬁths, S., Mitchison, D., & Mond, J. M. (2017).
The transition from thinness-oriented to muscularity-oriented
disordered eating in adolescent males: A clinical observation.
Journal of Adolescent Health, 60(3), 353–355. doi:10.1016/j.
jadohealth.2016.10.014
*Murray, S. B., Grifﬁths, S., Mond, J. M., Kean, J., & Blashill,
A. J. (2016). Anabolic steroid use and body image psychopa-
thology in men: Delineating between appearance-versus
performance-driven motivations. Drug and Alcohol Depen-
dence, 165, 198–202. doi:10.1016/j.drugalcdep.2016.06.008
Murray, S. B., Nagata, J. M., Grifﬁths, S., Calzo, J. P., Brown, T. A.,
Mitchison, D., Blashill, A. J., & Mond, J. M. (2017). The
enigma of male eating disorders: A critical review and synthesis.
Clinical Psychology Review, 57, 1–11. doi:10.1016/j.
cpr.2017.08.001
*Murray, S. B., Rieger, E., Hildebrand, T., Karlov, L., Russell, J.,
Boon, E., Dawson, R. T., & Touyz, S. W. (2012). A
comparison of eating, exercise, shape, and weight related
symptomatology in males with muscle dysmorphia and
anorexia nervosa. Body Image, 9(2), 193–200. doi:10.1016/j.
bodyim.2012.01.008
Nieuwoudt, J. E., Zhou, S., Coutts, R. A., & Booker, R. (2012).
Muscle dysmorphia: Current research and potential classiﬁca-
tion as a disorder. Psychology of Sport and Exercise, 13(5),
569–577. doi:10.1016/j.psychsport.2012.03.006
*Nieuwoudt, J. E., Zhou, S., Coutts, R. A., & Booker, R. (2015).
Symptoms of muscle dysmorphia, body dysmorphic disorder,
and eating disorder in a nonclinical population of adult
male weightlifters of Australia. Journal of Strength and Con-
ditioning Research, 29(5), 1406–1414. doi:10.1519/JSC.
0000000000000763
Olivardia, R. (2001). Mirror, mirror on the wall, who’s the largest
of them all? The features and phenomenology of muscle
dysmorphia. Harvard Review of Psychiatry, 9(5), 254–259.
doi:10.1080/10673220127900
*Olivardia, R., Pope, H. G., & Hudson, J. I. (2000). Muscle
dysmorphia in male weightlifters: A case-control study. Amer-
ican Journal of Psychiatry, 157(8), 1291–1296. doi:10.1176/
appi.ajp.157.8.1291
Pope, H. G., Gruber, A. J., Choi, P., Olivardia, R., & Phillips, K. A.
(1997). Muscle dysmorphia: An underrecognized form of body
dysmorphic disorder. Psychosomatics, 38(6), 548–557.
doi:10.1016/S0033-3182(97)71400-2
Pope, H. G., Katz, D. L., & Hudson, J. I. (1993). Anorexia nervosa
and “reverse anorexia” among 108 male bodybuilders.
Comprehensive Psychiatry, 34(6), 406–409. doi:10.1016/
0010-440X(93)90066-D
Pope, H. G., Khalsa, J. H., & Bhasin, S. (2017). Body image
disorders and abuse of anabolic-androgenic steroids among
men. JAMA-Journal of the American Medical Association,
317(1), 23–24. doi:10.1001/jama.2016.17441
Pope, H. G., Phillips, K. A., & Olivardia, R. (2000). The Adonis
complex: The secret crisis of male body obsession. New York,
NY: The Free Press.
*Pope, C. G., Pope, H. G., Menard, W., Fay, C., Olivardia, R., &
Phillips, K. A. (2005). Clinical features of muscle dysmorphia
among males with body dysmorphic disorder. Body Image, 2,
395–400. doi:10.1016/j.bodyim.2005.09.001
Raudenbush, S. W. (2009). Analyzing effect sizes: Random-effects
models. In H. Cooper, L. V. Hedges, & J. C. Valentine (Eds.),
The handbook of research synthesis and meta-analysis (2nd
ed., pp. 295–315). New York: Russell Sage Foundation.
Readdy, T., Cardinal, B. J., & Watkins, P. L. (2011).
Muscle dysmorphia, gender role stress, and sociocultural inﬂu-
ences: An exploratory study. Research Quarterly for Exercise
and Sport, 82, 310–319. doi:10.1080/02701367.2011.10599759
Journal of Behavioral Addictions 8(3), pp. 351–371 (2019) | 363
Muscle dysmorphia and eating disorders
*Rhea, D. J., Lantz, C. D., & Cornelius, A. E. (2004). Develop-
ment of the Muscle Dysmorphia Inventory (MDI). Journal of
Sports Medicine and Physical Fitness, 44, 428–435. Retrieved
from http://www.drdebbierhea.com/wp-content/uploads/2013/
05/Development-of-the-MDI-2005.pdf
Robert, C. A., Munroe-Chandler, K. J., & Gammage, K. L. (2009).
The relationship between the drive for muscularity and muscle
dysmorphia in male and female weight trainers. The Journal of
Strength and Conditioning Research, 23(6), 1656–1662.
doi:10.1519/JSC.0b013e3181b3dc2f
Sánchez-Meca, J., & Marín-Martínez, F. (2008). Conﬁdence
intervals for the overall effect size in random-effects meta-
analysis. Psychological Methods, 13(1), 31–48. doi:10.1037/
1082-989X.13.1.31
Sánchez-Meca, J., Marín-Martínez, F., & Chaco´n-Moscoso, S.
(2003). Effect-size indices for dichotomized outcomes in
meta-analysis. Psychological Methods, 8(4), 448–467.
doi:10.1037/1082-989X.8.4.448
Sandgren, S. S., & Lavallee, D. (2018). Muscle dysmorphia
research neglects DSM-5 diagnostic criteria. Journal of
Loss and Trauma, 23(3), 211–243. doi:10.1080/15325024.
2018.1428484
*Santarnecchi, E., & Dèttore, D. (2012). Muscle dysmorphia in
different degrees of bodybuilding activities: Validation of the
Italian version of Muscle Dysmorphia Disorder Inventory and
bodybuilder image grid. Body Image, 9(3), 396–403.
doi:10.1016/j.bodyim.2012.03.006
Schmidt, F. L., & Hunter, J. E. (2015). Methods of meta-analysis:
Correcting error and bias in research synthesis (3rd ed.).
Thousand Oaks, CA: Sage.
*Segura-García, C., Ammendolia, A., Procopio, L., Papaianni, M. C.,
Sinopoli, F., Bianco, C., De Fazio, P., & Capranica, L. (2010).
Body uneasiness, eating disorders and muscle dysmorphia in
individuals who overexercise. Journal of Strength and
Conditioning Research, 24(11), 3098–3104. doi:10.1519/JSC.
0b013e3181d0a575
Short, J. (2005). Creating a tool to measure muscle dysmorphia
(Unpublished master’s thesis). Western Kentucky University,
Bowling Green, KY.
*Sladek, M. R., Engeln, R., & Miller, S. A. (2014). Development
and validation of the Male Body Talk Scale: A psychometric
investigation. Body Image, 11(3), 233–244. doi:10.1016/j.
bodyim.2014.02.005
Sterne, J. A. C., & Egger, M. (2005). Regression methods to detect
publication and other bias in meta-analysis. In H. R. Rothstein,
A. J. Sutton, & M. Borenstein (Eds.), Publication bias in meta-
analysis: Prevention, assessment and adjustments (pp. 99–100).
Chichester, UK: Wiley.
Suffolk, M. T., Dovey, T. M., Goodwin, H., & Meyer, C. (2013).
Muscle dysmorphia: Methodological issues, implication for
research. Eating Disorders, 21(5), 437–457. doi:10.1080/
10640266.2013.828520
Tod, D., & Edwards, C. (2015a). Relationships among muscle
dysmorphia characteristics, body image, quality of life, and
coping in males. Journal of Science and Medicine in Sport,
18(5), 585–589. doi:10.1016/j.jsams.2014.07.015
Tod, D., & Edwards, C. (2015b). A meta-analysis of the drive for
muscularity’s relationships with exercise behaviour, disordered
eating, supplement consumption, and exercise dependence.
International Review of Sport and Exercise Psychology,
8(1), 185–203. doi:10.1080/1750984X.2015.1052089
Tod, D., Edwards, C., & Cranswick, I. (2016). Muscle dysmor-
phia: Current insights. Journal of Psychology Research and
Behavior Management, 9, 179–188. doi:10.2147/PRBM.
S97404
*Walker, D. C., Anderson, D. A., & Hildebrandt, T. (2009). Body
checking behaviors in men. Body Image, 63, 164–170.
doi:10.1016/j.bodyim.2009.05.001
364 | Journal of Behavioral Addictions 8(3), pp. 351–371 (2019)
Badenes-Ribera et al.
APPENDIX A: CHECKLIST FOR ASSESSING THE METHODOLOGICAL
QUALITY OF THE STUDIES
Item Description
1 Representative sampling procedures (Yes: 1; No: 0)
2 The inclusion and exclusion criteria of participants were suitable to represent clinical or at risk population for MD and ED (Yes: 1;
No: 0)
3 Dropouts were similar in sociodemographic characteristics to those of the ﬁnal sample (completers) (Yes: 1; No: 0; Unable to
determine: 0)
4 The measurement instrument used to assess MD show good psychometric properties (validity and reliability) in the sample of study
(Yes: 1; No: 0; Unable to determine: 0)
5 The measurement instrument used to assess ED shows good psychometric properties (validity and reliability) in the sample of study
(Yes: 1; No: 0; Unable to determine: 0)
6 The assessment of DM and ED was not dichotomized (Yes: 1; No: 0)
7 Absence of reporting bias: results for all MD and ED instruments described in “Methods” section were reported (Yes: 1; No: 0)
8 The statistical test used to assess the relationships between MD and ED was appropriate to the data (non-parametric methods vs.
parametric methods) (Yes: 1; No: 0; Unable to determine: 0)
9 Absence of private ﬁnancial support (Yes: 1; No: 0)
10 Statistical power: sample sizes have been calculated to detect an effect (Yes: 1; No: 0; Unable to determine: 0)
Note. The methodological quality checklist consisted of 10 criteria with a dichotomous response scale. The presence of the criterion is given
1 point and its absence 0 points. The total score was 10 points. MD: muscle dysmorphia; ED: eating disorders.
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APPENDIX C: METHODOLOGICAL QUALITY OF THE STUDIES
Study
Methodological quality criteria
1 2 3 4 5 6 7 8 9 10 Total (0–10)
Babusa and Túry (2012) 0 1 0 1 0 1 1 1 0 0 5
Babusa et al. (2012) 0 1 0 1 0 1 1 1 1 0 6
Baile et al. (2011) 0 1 0 0 1 1 1 0 1 0 5
Bo et al. (2014) 0 0 0 0 0 0 1 1 1 0 3
Brown et al. (2017) 0 1 0 1 1 1 1 1 0 0 6
Cafri et al. (2008) 0 1 0 0 0 0 1 1 1 1 5
Castro Lo´pez et al. (2013) 1 1 0 0 0 1 1 0 1 0 5
De Santis et al. (2011) 0 0 0 1 1 1 1 1 0 1 6
Dryer et al. (2016) 0 0 0 1 1 1 1 1 1 0 6
Giardino and Procidano (2012): Study 1 0 1 0 1 1 1 1 0 1 0 6
Giardino and Procidano (2012): Study 2 0 1 0 1 1 1 1 0 1 0 6
Giardino and Procidano (2012): Study 3 0 1 0 1 1 1 1 0 1 0 6
Giardino and Procidano (2012): Study 4 0 1 0 1 1 1 1 0 1 0 6
Goodale et al. (2001) 0 0 0 1 1 1 1 1 1 0 6
Guidi et al. (2013) 0 1 0 0 0 1 1 0 1 0 4
Hale et al. (2013) 0 1 0 1 1 1 1 0 1 0 6
Hildebrandt et al. (2004) 0 1 0 1 1 1 1 0 1 0 6
Hildebrandt et al. (2006) 0 1 0 1 1 1 0 1 1 0 6
Hildebrandt et al (2010) 0 0 0 0 0 1 1 0 1 0 3
Hildelbrandt et al. (2011) 0 1 0 1 1 1 1 0 1 0 6
Hildebrandt et al. (2012) 0 0 0 1 1 1 1 1 1 0 6
Hughes et al. (2016) 0 0 0 1 1 1 1 1 1 0 6
Jin et al. (2015) 0 1 0 1 1 1 1 1 1 0 7
Kanayama et al. (2006) 0 1 0 0 0 1 1 0 0 0 3
Klimek et al. (2018) 0 0 0 1 1 1 1 1 1 0 6
Lamanna et al. (2010): Study 1 0 0 0 1 1 1 1 1 1 0 6
Lamanna et al. (2010): Study 2 0 0 0 1 1 1 1 1 1 0 6
Latorre-Román et al. (2014) 0 1 0 1 1 1 1 0 1 0 6
Lopez et al. (2015) 0 0 0 0 0 1 1 0 1 0 3
Magallares (2016) 0 0 0 1 1 1 1 0 1 0 5
Maida et al. (2005) 0 1 0 0 0 1 1 0 1 0 4
McFarland and Kaminski (2009) 0 0 0 1 0 1 1 0 1 0 4
Mitchell, Murray, Cobley, et al. (2017) 0 1 0 1 1 1 1 1 0 0 6
Murray et al. (2012) 0 1 0 1 1 1 1 1 1 0 7
Murray et al. (2016) 0 1 0 1 1 1 1 1 1 0 7
Nieuwoudt et al. (2015) 0 1 0 1 1 1 1 1 1 0 7
Olivardia et al. (2000) 0 1 0 0 0 0 1 0 1 0 3
Pope et al. (2005) 0 1 0 0 0 1 1 0 1 0 4
Rhea et al. (2004) 0 1 0 1 1 1 1 1 1 0 7
Santarnecchi and Dettore (2012) 0 1 0 1 1 1 1 0 0 0 5
Segura-García et al. (2010): Sample 1 0 1 0 0 0 0 1 1 1 0 4
Segura-García et al. (2010): Sample 2 0 1 0 0 0 0 1 1 1 0 4
Segura-García et al. (2010): Sample 3 0 1 0 0 0 0 1 1 1 0 4
Sladek et al. (2014) 0 1 0 0 0 1 1 0 1 0 4
Walker et al. (2009) 0 0 0 1 1 1 1 1 1 0 6
Note. The methodological quality checklist consists of 10 criteria with a dichotomous response scale. The presence of the criterion is given
1 point and its absence 0 points. The total quality score for each study was obtained by summing the 1s and 0s through the 10 quality items
(see Appendix A for a description of the quality items).
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APPENDIX D
Funnel plot of the MD–ED effect sizes to assess publication
bias. White circles represent each of the studies included. The
absence of black circles indicates that the trim-and-ﬁll method
had not to impute missing data to symmetrize the funnel plot.














Funnel Plot of Standard Error by Fisher's Z
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